Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q2 2025 Earnings Conference Call August 7, 2025 5:30 PM ET
Company Participants
Daniel Waid Marshall – Senior Manager of Communications and Ownership
Jason Kelly – Founder, CEO & Director
Steven P. Coen – Chief Accounting Officer & CFO
Daniel Waid Marshall
Good evening. I’m Daniel Marshall, Senior Manager of Communications and Ownership. I’m joined by Jason Kelly, our Co-Founder and CEO; and our new CFO, Steve Coen. Thanks, as always, for joining us. We’re looking forward to updating you on our progress.
As a reminder, during the presentation today, we’ll be making forward-looking statements, which involve risks and uncertainties. Please refer to our filings with the SEC to learn more about these risks and uncertainties, including our most recent 10-K. Today, in addition to updating you on the quarter results, we’re going to provide updates on our path towards adjusted EBITDA breakeven and dive deeper into the new deals and launches in Ginkgo’s Tools businesses, which continue to establish themselves as critical tools in AI-powered bioengineering. As usual, we’ll end with a Q&A session, and I’ll take questions from analysts, investors and the public. You can submit those questions to us in advance via #Ginkgoresults or e-mail investors@ginkgobioworks.com. All right. Over to you, Jason.
Jason Kelly
All right. Thanks, Daniel. We always start with our mission here at Ginkgo, which is to make biology easier to engineer. Our objectives are very similar to what you’ve heard from me over the last few earnings calls. We’re trying to reach adjusted EBITDA by the end — breakeven by the end of 2026, while maintaining a cash margin of safety, and I’m going to update on that in just a sec. We’re cutting costs while serving our current customers. And then very importantly, we’re expanding from an R&D solutions business into the life science tools space. And in the strategic section, you’re
#Ginkgo #Bioworks #Holdings #DNA #Earnings #Call #Transcript